Why Do Myeloma Patients Do Better At High Volume Facility?

Why Do Myeloma Patients Do Better At High Volume Facility?

Cancer-News

3 months
42 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Ashley T. Freeman, MD of BC Cancer explains commonly asked questions by colleagues: why do myeloma patients seem to do better when they are treated at a high volume facility or by high volume myeloma oncologist?

_______

New research adds to accumulating evidence of benefit for patients treated at high-volume facilities or by high-volume providers.

New research in the September 2019 issue of JNCCN—Journal of the National Comprehensive Cancer Network finds that providers with more experience treating people with multiple myeloma have better outcomes than those with more limited experience. In general, providers who saw the most cases were more likely to be located at academic, NCI-designated cancer centers. However, the researchers found that the very highest-volume providers at community facilities did achieve equally low mortality rates as clinicians at NCI-designated cancer centers.

“Multiple myeloma care is complicated and nuanced, with many specific treatments and management scenarios,” said senior researcher William A. Wood, MD, MPH, UNC Lineberger Comprehensive Cancer Center. “Our results show that provider experience, and potentially access to resources at a comprehensive cancer center, may improve survival in patients with multiple myeloma. The reasons might have to do with familiarity with the benefits and best use of newer drugs and regimens, access to resources to help with management of toxicities or complications, or other factors. Or, it might be that patients who are seen by higher volume providers are more likely to have other unmeasured or confounding factors associated with better survival. More research is needed to help sort this out.”

The study was based on data from 1,029 patients in the University of North Carolina Cancer Information and Population Health Resource (CIPHR) who were diagnosed with multiple myeloma between 2006 and 2012. People who did not have continuous insurance enrollment for 6 months before and 12 months after diagnosis were excluded, along with those who did not receive chemotherapy within 12 months of diagnosis. Patients ranged in age from 25 to 98 years, with a mean of 68.

Read here: https://www.oncologytube.com/video/study-in-jnccn-supports-idea-that-higher-patient-volumes-are-associated-with-longer-survival-in-multiple-myeloma

Up Next Autoplay
Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
Bayer to showcase new data including research in immuno-oncology at ASCO GI Cancers Symposium 2020
Category: News
2 Views
Cancer-News 1 day
Alternative Pain-Control Strategy Reduces Need for Opioids in Patients with Head and Neck Cancer
Alternative Pain-Control Strategy Reduces Need for Opioids in Patients with Head and Neck Cancer
Category: Head and Neck Cancers
2 Views
Cancer-News 2 days
JAVELIN Study: How Does This Affect Clinicians?
JAVELIN Study: How Does This Affect Clinicians?
Category: Urology
5 Views
Cancer-News 3 days
What happened to patients with progression of disease?
What happened to patients with progression of disease?
Category: Urology
3 Views
Cancer-News 3 days
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Phase III JAVELIN Study in Urothelial Cancer @tompowles1
Category: Urology
13 Views
Cancer-News 3 days
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Radiotherapy in Localized Prostate Cancer: What is next for treatment?
Category: Prostate Cancer
1 Views
Cancer-News 6 days
The Impact of Therapy with External-Beam Radiotherapy
The Impact of Therapy with External-Beam Radiotherapy
Category: Prostate Cancer
1 Views
Cancer-News 6 days
Is there a correlation between the target volume of radiation?
Is there a correlation between the target volume of radiation?
Category: Prostate Cancer
0 Views
Cancer-News 6 days
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
NantKwest and ImmunityBio Announce Complete Response in Metastatic Pancreatic Cancer in the First Patient to Receive PD-L1 Tumor-Targeted Natural Killer Cells (PD-L1.t-haNK) Combined with...
Category: Pancreatic Cancer
2 Views
Cancer-News 6 days
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial
Category: Prostate Cancer
11 Views
Cancer-News 6 days